Cell and Gene Therapy for Oncology Manufacturers Technological Advancements

Top Companies in the Cell and Gene Therapy for Oncology Market & Their Offerings

What are the Recent Developments in the Cell and Gene Therapy for Oncology Market? 

• In March 2026, Merck & Co. signed an MoU with Cyto-Facto to strengthen its cell and gene therapy manufacturing capabilities in the Asia-Pacific region. The collaboration focuses on improving lentiviral vector production and optimizing advanced manufacturing processes to support next-generation oncology therapies.
• In January 2026, Siren Biotechnology received U.S. FDA clearance for its first Investigational New Drug (IND) application, marking its transition into clinical-stage development. The therapy focuses on AAV-based immuno-gene therapy for treating recurrent high-grade glioma, a highly aggressive brain tumor. This milestone highlights growing innovation in oncology gene therapies along with increasing regulatory support for next-generation cancer treatments.

Supply Chain Analysis

R&D

• Research and development in cell and gene therapies for oncology is progressing quickly, with a strong focus on improving CAR-T cell effectiveness, expanding applications to solid tumors, and advancing in vivo gene editing technologies to achieve better patient outcomes.
• Key Players: Novartis, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, and Fate Therapeutics

Clinical Trials

• Clinical trials in oncology cell and gene therapies are progressing quickly, targeting hard-to-treat cancers such as lung cancer, prostate cancer, and glioblastoma. They focus on innovative approaches like CAR T-cell therapy, oncolytic viruses, and gene-modified stem cells to enhance immune response against tumors.
• Key players: Novartis, Gilead Sciences, Bristol Myers Squibb, AstraZeneca, and Merck & Co.

Patient Support and Services

• Patient support in oncology cell and gene therapies is centered on guiding patients through complex treatment journeys like CAR-T therapy by providing personalized care coordination, financial aid, travel assistance, and end-to-end logistical support. These services are often delivered through specialized patient support programs and treatment hubs to ensure smoother access to advanced therapies.
• Key Players: Novartis, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, and Johnson & Johnson

Market Growth

The global cell and gene therapy for oncology market size was estimated at USD 14.82 billion in 2025 and is predicted to increase from USD 18.48 billion in 2026 to approximately USD 134.53 billion by 2035, expanding at a CAGR of 24.68% from 2026 to 2035.